Hong P, Liu R, Rai S, Liu J, Zhou Y, Zheng Y, et al. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res. 2023;18:116. https://doi.org/10.1186/s13018-023-03595-x.

Article  PubMed  PubMed Central  Google Scholar 

Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46–56. https://doi.org/10.5152/eurjrheum.2016.048.

Article  PubMed  Google Scholar 

Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus. 2022;6:e10665. https://doi.org/10.1002/jbm4.10665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossini M, Cantatore FP, Del Puente A, Frediani B, Gatti D, Giannini S, et al. Expert opinion on the management of patients with osteoporosis with anabolic drugs in Italy. Reumatismo. 2024;76:2. https://doi.org/10.4081/reumatismo.2024.1696.

Article  Google Scholar 

Dong B, Zhou Y, Wang J, Li C, Fu Z, Huang Y, et al. Comparison of bisphosphonates versus teriparatide in therapy of the glucocorticoid-induced osteoporosis (GIOP): a meta-analysis of randomized controlled trials. Horm Metab Res. 2023;55:236–44. https://doi.org/10.1055/a-2015-1747.

Article  CAS  PubMed  Google Scholar 

Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res. 2019;34:632–42. https://doi.org/10.1002/jbmr.3641.

Article  PubMed  Google Scholar 

Dito G, Lugaresi M, Degradi C, Guabello G, Longhi M, Corbetta S. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study. Endocrine. 2023;82:181–9. https://doi.org/10.1007/s12020-023-03431-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6:99–105. https://doi.org/10.1038/nrrheum.2009.260.

Article  PubMed  Google Scholar 

Ebina K, Etani Y, Noguchi T, Nakata K, Okada S. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2024(1). https://doi.org/10.1007/s00774-024-01536-0.

Liu J, Laster A, Xu X, Guo H, Oates M, Gandra SR. Patterns of teriparatide and sequential antiresorptive agent treatment among elderly female medicare beneficiaries. J Bone Miner Res. 2021;36:2309–16. https://doi.org/10.1002/jbmr.4439.

Article  CAS  PubMed  Google Scholar 

Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M, et al. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021;33:759–73. https://doi.org/10.1007/s40520-021-01817-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–45. https://doi.org/10.4065/83.9.1032.

Article  CAS  PubMed  Google Scholar 

Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–40. https://doi.org/10.1016/S0140-6736(17)32137-2.

Article  CAS  PubMed  Google Scholar 

Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int. 2017;28:799–809. https://doi.org/10.1007/s00198-016-3888-9.

Article  CAS  PubMed  Google Scholar 

Mitlak BH. Parathyroid hormone as a therapeutic agent. Curr Opin Pharmacol. 2002;2:694–9. https://doi.org/10.1016/s1471-4892(02)00208-4.

Article  CAS  PubMed  Google Scholar 

Martin TJ. Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab. 2014;21:8–20. https://doi.org/10.11005/jbm.2014.21.1.8.

Article  PubMed  PubMed Central  Google Scholar 

Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:855–64. https://doi.org/10.1359/jbmr.060314.

Article  CAS  PubMed  Google Scholar 

Gagnon C, Li V, Ebeling PR. Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment. Clin Interv Aging. 2008;3:635–45. https://doi.org/10.2147/cia.s3372.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka S. Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Rev. 2019;4:158–64. https://doi.org/10.1302/2058-5241.4.180018.

Article  PubMed  PubMed Central  Google Scholar 

Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–16. https://doi.org/10.1056/NEJMra067395.

Article  CAS  PubMed  Google Scholar 

Chopra K, Malhan N. Teriparatide for the treatment of medication-related osteonecrosis of the jaw. Am J Ther. 2020;28:e469–77. https://doi.org/10.1097/MJT.0000000000001182.

Article  PubMed  Google Scholar 

Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int. 2022;33:1703–14. https://doi.org/10.1007/s00198-022-06413-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6:24–30. https://doi.org/10.1007/s11914-008-0005-9.

Article  PubMed  Google Scholar 

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41. https://doi.org/10.1056/NEJM200105103441904.

Article  CAS  PubMed  Google Scholar 

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024–30. https://doi.org/10.1001/archinte.164.18.2024.

Article  PubMed  Google Scholar 

Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008;19:87–94. https://doi.org/10.1007/s00198-007-0485-y.

Article  CAS  PubMed  Google Scholar 

Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Min Res. 2004;19:745–51. https://doi.org/10.1359/jbmr.040117.

Article  CAS  Google Scholar 

Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int. 2010;21:2027–36. https://doi.org/10.1007/s00198-009-1168-7.

Article  CAS  PubMed  Google Scholar 

Wang WY, Chen LH, Ma WJ, You RX. Drug efficacy and safety of denosumab, teriparatide, Zoledronic acid, and Ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2023;27:8253–68. https://doi.org/10.26355/eurrev_202309_33586.

Article